Belite Bio (BLTE)

• Market cap: $6.47B
• 1 day: -2.94%
• 5 days: -7.37%
• 1 month: -3.23%
• 3 months: 15.05%
• 6 months: 162.5%
• Year to date: 8.35%
• 1 year: 185.9%
• 5 years: 1,529.56%
• 10 years: 1,529.56%
• Sector: Healthcare
• Industry: Biotechnology

About: Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

Employees: 25